Non-Muscle Invasive Bladder Neoplasms clinical trials

The registry lists 294 studies for Non-Muscle Invasive Bladder Neoplasms across more than 10 countries. 126 are recruiting or about to start. 256 of them are mainly about Non-Muscle Invasive Bladder Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Non-Muscle Invasive Bladder Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 92
Completed: 80
Not yet recruiting: 32
Active, not recruiting: 31
Terminated: 23
Status unknown: 22

Phase

Phase 2: 97
Phase 1: 72
Phase 3: 54
Phase 4: 9
Early Phase 1: 2

Where

United States: 114
China: 50
Italy: 29
Spain: 27
France: 26
Canada: 26

Who runs them

UroGen Pharma Ltd. (11) · Mansoura University (10) · Janssen Research & Development, LLC (7) · ImmunityBio, Inc. (7) · CG Oncology, Inc. (4) · Ferring Pharmaceuticals (4) · Pfizer (4) · University of Rome Tor Vergata (4)

What is being tested here

Drugs under test in Non-Muscle Invasive Bladder Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Gemcitabine	10	2	19
BCG Vaccine	6	7	17
Mitomycin	5	7	16
Docetaxel	5	1	8
Disitamab vedotin	5	0	6
BCG Solution	3	0	3
Picibanil	2	1	4
Lyophilized Inactivated Group A Streptococcus TARA-002	2	1	4
Efserakefusp alfa	2	1	2
Cretostimogene grenadenorepvec	1	2	5

Drug classes tested here Antimetabolites 11 open · Antimitotic agents 7 open · Antibody-drug conjugates (ADCs) 5 open · Tyrosine kinase inhibitors (TKIs) 4 open · Immune checkpoint inhibitors 3 open

Coming up

28phase 3 studies under way

44studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT · Phase 3 · CG Oncology, Inc.
Jun 20271 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors · Phase 3 · dmitry enikeev
Jun 2027Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients · Phase 3 · Shaogang Wang
Nov 2026Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations · Tyra Biosciences, Inc
Nov 2026Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer · ImmunityBio, Inc.
Nov 2026T-Control® Safety for Cytostatics Management · Rethink Medical SL
Nov 2026CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC · S. Andrea Hospital
Nov 2026The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer · Tianjin Medical University Second Hospital
Nov 2026Effects of Microbiological and Immunological Factors on the Lower Urinary Tract · University of Zurich
Dec 2026The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer · Assiut University

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger. 2 (2%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 92
Age	Women	Men
10	2 (2%)	2 (2%)
18	89 (97%)	90 (98%)
30	91 (99%)	92 (100%)
40	91 (99%)	92 (100%)
50	91 (99%)	92 (100%)
65	91 (99%)	92 (100%)
75	91 (99%)	92 (100%)
85	82 (89%)	83 (90%)

Across all 294 studies, recruiting or not: 4% stop at 75 or younger and <1% at 65; 5% take children; 0% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Non-Muscle Invasive Bladder Neoplasms studies take

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	43 mo19–61 · 24 studies	—	—
Observational	42 mo30–… · 29 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?Oct 15, 2026NCT07625527

Newly registered5

Studies

Recruiting first, then most recently updated. Showing 50 of 294. Browse all 294 → or search them.